COMPARATIVE STUDY BETWEEN A COMPLEX OF FLAVONOIDS AND POLYPHENOLS CREATED FROM EXTRACTS OF ARTICHOKE AND SARSAPRILLA AND A PLACEBO IN ALCOHOL RELATED LIVER DISEASE DECEMBER 12 1998
DOUBLE BLIND STUDY: 2nd Double Blind Study
In a previous study completed over two years ago in this same hospital an extract of artichoke (Cynara Floridanum) and sarsaparilla (Smilax Aristolochiaefolia) was evaluated in addressing the symptoms related to alcoholic liver disease. This study was accomplished over a fifteen-day period with exceptional results. Because of these results noted over a very short period of time, the hospital researchers were anxious to set up the same study over a longer period (30 days). Please refer to the July 3, 1996, study for descriptions of symptoms and study parameters. Results of this study are as follows:
A 72.38% reduction of the accumulation of serous abdominal fluid was noted in the treated group. The placebo saw a 6.35% increase in abdominal fluid.
A 66.08% reduction of symptoms related to encephalopathy was noted in the treated group. The placebo group saw a 12.24% increase in these symptoms.
The treated group experienced a 93.33% reduction in enlarged livers. In the placebo group their livers continued to enlarge by another 7.14%.
An 88.40% reduction in spleen enlargement was noted with the treated group. The placebo group worsened by 11.54%.
The treated group noted a 73.64% increase in strength. There was a decrease in muscle strength by 7.41% in the placebo group.
Edema in the extremities of the treated patients decreased by 48.21%. There was no change in the placebo group.
The treated group noted a 100% decrease in capillary hemorrhaging in the skin gums and nasal membranes. The placebo group saw an increase of 28.57% in hemorrhaging.
Loss of appetite decreased in the treated group by 76.98%. The placebo group noted a decrease of 3.70%.
ABDOMINAL WALL VEINS
The treated group experienced a 60.62% decrease in tortuous veins in the abdomen related to ascites. The placebo group saw a 3.33% decrease.
The treated group noted a 26.67% decrease in red and swollen palms. In the placebo group there was no change.
A 60.00% reduction in vascular lesions was noted in the treated group. A 3.33% reduction was seen in the placebo group.
The treated group noted a reduction of total bilirubin by 38.95%. The placebo group increased by 5.68%.
The treated group obtained 25.91% reduction in alkaline phosphates. There was an 11.69% increase in the placebo group.
SERUM GLUTAMIC OXALCETIC TRANSAMINASE (SGOT)
The treated group noted a decrease of 23.83% in SGOT levels. The placebo group experienced a worsening of 11.71%.
A 42.00% reduction in clotting time was noted with the treated group. An increase in clotting time was noted in the placebo group of 6.60%.
An increase of 37.27% in serum albumin was noted in the treated group. There was a decrease in the placebo group of 1.95%.
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT)
The treated group noted a reduction of 23.79% in GGT. The placebo group experienced an increase of 9.92%.